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ABSTRACT
Background and objectives:
This study was done to assess effect of additional anticonvulsant dose given during
supratentorial craniotomies on recovery time, haemodynamics, depth of anesthesia,
incidence of post operative seizures within 48 hours and plasma anticonvulsant levels.
This study enabled us to compare these factors in patients receiving the regular dose
of anticonvulsant with additional bolus dose of anticonvulsant.
Patient and Methods:
After getting approval from the Institutional Review Board (IRB) and Ethics
Committee of our institution, this study was carried out.  After getting informed
patient consent, a total of 36 patients who underwent supratentorial craniotomy who
fulfilled the inclusion criteria were recruited for this study. This study recruited
patients within the time frame of March 2015- August 2015. Patients were divided
into 2 groups, of which one group received the regular dose of anticonvulsant (regular
group) and the other received an additional dose (additional group) during surgery.
Patients were assessed preoperatively and anaesthetized according to our standard
institutional protocol. Apart from routine noninvasive monitoring, haemodynamics
was monitored by using an invasive arterial line and the depth of anaesthesia was
monitored using Bispectral index monitor. Anticonvulsant was administered during
craniotomy and the haemodynamics and changes in BIS were noted during and 1 hour
after administration of the anticonvulsant. Plasma anticonvulsant levels were
measured before and after craniotomy. Each patient was followed up till they were
fully oriented to time place and person. The specific time periods of cutting anesthetic
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agent to extubation, time to open eyes, time to obey commands and time to orientation
to time place and person were noted.  Patients were followed up for a period of
48hours to note the occurrence of seizures.
Results :
36 patients were studied, 19 patients received regular dose of anticonvulsant whereas
17 received an additional dose during craniotomy. The two groups were comparable
in distribution of age, sex, weight, tumor location and tumor pathology. The dose of
propofol and fentanyl administered during surgery, duration of anesthesia was
comparable.  There was no significant difference in recovery time when the 2 groups
were analyzed as additional dose (Phenytoin +Valproate) and regular dose (Phenytoin
+ Valproate) however, the subgroup analysis showed significant delay in recovery
especially time to obey commands (>15 min) and time to get orientation (>1 hr) in
patients who received an additional dose of phenytoin when compared with those who
received the regular phenytoin dose. Though these differences looked clinically very
significant it was not statistically significant. Hemodynamic fluctuations were
clinically significant in the additional phenytoin group, but not statistically significant.
There was marginal decrease in BIS values during administration of anticonvulsants.
Plasma anticonvulsant levels had significantly dropped in patients who received
regular dose (p 0.004). There was a positive correlation between the amount of
intravenous fluid administration and drop in plasma anticonvulsant level. Five out of
36 patients had seizures during the immediate postoperative period. Out of these 5, 4
patients had preoperative seizure. Out of 5 who had post operative seizure, two had
sub-therapeutic plasma level. We felt that the occurrence of seizures had no
correlation with post operative plasma anticonvulsant levels.
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Conclusion:
Administration of additional dose of Phenytoin causes delay in recovery and
haemodynamic fluctuation during surgery. Administration of additional dose of
sodium valproate did not affect either the recovery time, or the haemodynamics.
Presence of preoperative seizures is one of the significant risk factor for developing
post operative seizure.  Since there is a correlation between the amount of IVF
administered, blood loss and the decline in plasma level of anticonvulsant,
administration of an additional anticonvulsant in patients who are resuscitated with
large amount of IVF will definitely help to restore the plasma anticonvulsant level.
Due to the small sample size, it is very difficult to comment on occurrence of post
operative seizures and the plasma anticonvulsant level. This warrants larger
randomized control trials to see the correlation statistically. This study gave us an
insight into a probable reason for delay in recovery post craniotomy.
Keywords: anticonvulsant prophylaxis, brain tumors, phenytoin, Valproate,
hemodynamics, bispectral index,seizures.
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ABSTRACT
Background and objectives:
This study was done to assess effect of additional anticonvulsant dose given during
supratentorial craniotomies on recovery time, haemodynamics, depth of anesthesia, incidence of
post operative seizures within 48 hours and plasma anticonvulsant levels. This study enabled us
to compare these factors in patients receiving the regular dose of anticonvulsant with additional
bolus dose of anticonvulsant.
Patient and Methods:
After getting approval from the Institutional Review Board (IRB) and Ethics Committee of our
institution, this study was carried out.  After getting informed patient consent, a total of 36
patients who underwent supratentorial craniotomy who fulfilled the inclusion criteria were
recruited for this study. This study recruited patients within the time frame of March 2015-
August 2015. Patients were divided into 2 groups, of which one group received the regular dose
of anticonvulsant (regular group) and the other received an additional dose (additional group)
during surgery.
Patients were assessed preoperatively and anaesthetized according to our standard institutional
protocol. Apart from routine noninvasive monitoring, haemodynamics was monitored by using
an invasive arterial line and the depth of anaesthesia was monitored using Bispectral index
monitor. Anticonvulsant was administered during craniotomy and the haemodynamics and
changes in BIS were noted during and 1 hour after administration of the anticonvulsant. Plasma
anticonvulsant levels were measured before and after craniotomy. Each patient was followed up
till they were fully oriented to time place and person. The specific time periods of cutting
anesthetic agent to extubation, time to open eyes, time to obey commands and time to orientation
to time place and person were noted.  Patients were followed up for a period of 48hours to note
the occurrence of seizures.
Results :
36 patients were studied, 19 patients received regular dose of anticonvulsant whereas 17 received
an additional dose during craniotomy. The two groups were comparable in distribution of age,
sex, weight, tumor location and tumor pathology. The dose of propofol and fentanyl
administered during surgery, duration of anesthesia was comparable.  There was no significant
difference in recovery time when the 2 groups were analyzed as additional dose (Phenytoin
+Valproate) and regular dose (Phenytoin + Valproate) however, the subgroup analysis showed
significant delay in recovery especially time to obey commands (>15 min) and time to get
orientation (>1 hr) in patients who received an additional dose of phenytoin when compared with
those who received the regular phenytoin dose. Though these differences looked clinically very
significant it was not statistically significant. Hemodynamic fluctuations were clinically
significant in the additional phenytoin group, but not statistically significant. There was marginal
decrease in BIS values during administration of anticonvulsants. Plasma anticonvulsant levels
had significantly dropped in patients who received regular dose (p 0.004). There was a positive
correlation between the amount of intravenous fluid administration and drop in plasma
anticonvulsant level. Five out of 36 patients had seizures during the immediate postoperative
period. Out of these 5, 4 patients had preoperative seizure. Out of 5 who had post operative
seizure, two had sub-therapeutic plasma level. We felt that the occurrence of seizures had no
correlation with post operative plasma anticonvulsant levels.
Conclusion:
Administration of additional dose of Phenytoin causes delay in recovery and haemodynamic
fluctuation during surgery. Administration of additional dose of sodium valproate did not affect
either the recovery time, or the haemodynamics. Presence of preoperative seizures is one of the
significant risk factor for developing post operative seizure.  Since there is a correlation between
the amount of IVF administered, blood loss and the decline in plasma level of anticonvulsant,
administration of an additional anticonvulsant in patients who are resuscitated with large amount
of IVF will definitely help to restore the plasma anticonvulsant level. Due to the small sample
size, it is very difficult to comment on occurrence of post operative seizures and the plasma
anticonvulsant level. This warrants larger randomized control trials to see the correlation
statistically. This study gave us an insight into a probable reason for delay in recovery post
craniotomy.
Keywords: anticonvulsant prophylaxis, brain tumors, phenytoin, Valproate, hemodynamics,
bispectral index,seizures.
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INTRODUCTION
Seizures are the most common neurological disorder with a prevalence
of 0.5%-1%.(1) Seizures pose devastating complications such as loss of
consciousness, aspiration of gastric contents, permanent neurological damage.
Anticonvulsants are drugs used to control seizures or to prevent seizures
(prophylaxis) in the vulnerable population.
Anticonvulsant use began mainly for therapeutic purposes, to terminate
an ongoing episode of seizure. However in the recent past, they have been in
use for prophylaxis in patients with brain tumors. In patients with brain tumors
who present with seizures, use of an anticonvulsant is rational and also
recommended by American Academy of Neurology (2002). Use of
anticonvulsants in patients with brain tumors, who do not present with seizures,
is still controversial. According to the American Academy of Neurology, the
use of anticonvulsants is not recommended, if patients with brain tumours do
not present with seizures(2). But still it is used commonly in our country,
because of the devastating complications of the seizures during the
perioperative period.
As Anaesthesiologists, we administer anticonvulsants, either as the
regular dose or an additional dose during the intraoperative period according to
the surgeon’s preference. Anticonvulsants may inhibit or induce hepatic
enzymes, and therefore alter the blood levels of anaesthetic drugs especially
non depolarizing muscle relaxants. They can also decrease the efficacy of
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steroids such as dexamethasone, which the patient will receive during the
perioperative period to reduce the cerebral edema. Anticonvulsants can also
reduce the efficiency of chemotherapeutic agents. Allergic reactions, toxicity
and cardiac arrest have been reported with the use of them. It can also interfere
with cognition and recovery from anaesthesia especially when they are above
therapeutic range(3). Since blood levels are not routinely measured, deficits in
cognition and recovery are most often attributed to the residual anaesthetic
effect, cerebral edema, surgical handling or surgical complications such as
tumour bed haematoma, hence the diagnosis of anticonvulsant toxicity is often
misdiagnosed. The possibility of high levels of anticonvulsants as a reason for
delayed recovery and for the cognitive dysfunction post craniotomy ought to be
considered.
In this dissertation we aspire to observe whether administration of bolus
or additional dose of anticonvulsant has an effect on recovery from anaesthesia,
haemodynamics, depth of anaesthesia, incidence of post operative seizures and
the change in plasma anticonvulsant level during supratentorial craniotomy.
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AIMS AND OBJECTIVES
Aim:
To assess whether an additional dose of anticonvulsant given during the
intraoperative period affects the recovery time after supratentorial
craniotomy.
Objectives:
To assess the effect of prophylactic additional anticonvulsants on
1. Time to recovery from anaesthesia – Primary Outcome
2. Hemodynamic changes
3. Depth of Anaesthesia Secondary outcomes
4. Incidence of post operative seizure in first 48hours
5. Plasma anticonvulsant levels
-in patients undergoing supratentorial craniotomy.
Hypothesis
Additional anticonvulsants administered during neurosurgical
procedures, cause excessive plasma levels leading to hemodynamic changes,
increased sedation and delayed recovery in  patients undergoing supratentorial
craniotomies.
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REVIEW OF LITERATURE
Introduction to Neuroanaesthesia
Providing anesthesia for neurosurgical patients requires a sound
knowledge of cerebrovascular anatomy, physiology as well as the impact of
anesthetic agents on them. Neurosurgical procedures range from burr holes for
extradural hematomas to more surgically challenging excision of tumors and
cerebral aneurysm clipping requiring efficient anesthetic management.
The occurrence of brain tumor is a common entity. Brain tumors can
classified as primary or secondary depending upon the site of origin. They can
be classified as benign or malignant according to their histopathology. They
may be further classified into supratentorial or infratentorial according to their
location. More than 80% of brain tumors in adults are supratentorial, the
commonest being gliomas (36%), meningiomas (32.1%) and pituitary
adenomas (8.4%)(4). Approximately fifty percent of the tumors are malignant.
The five most common sources of brain metastases are breast, colorectal,
kidney, lung and melanoma. As there is no organized brain tumor registry in
India, it is difficult to obtain epidemiologic data for our country.  Age-adjusted
incidence rate of primary brain tumor in India is 3.9 per 100,000 population for
males and 2.4 per 100,000 populations for females, with a male preponderance
for all histological classification(5).
Apart from the routine preoperative evaluation that we do all cases,
neurosurgical cases need documentation of tumor location and size, presence of
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seizure and its type, neurological deficits and evidence of raised intracranial
pressure. Medications such as anticonvulsants and steroids have to be
evaluated and optimized before surgery.
Anesthetic management of supratentorial tumors involves optimization
of intracranial pressure. Intracranial pressure is governed by 3 factors- cerebral
blood volume, cerebrospinal fluid and brain matter. A rise in any of these
entities contributes for a raised intracranial pressure. Cautious induction and
intubation to avoid hemodynamic fluctuations is warranted. Drop in blood
pressure during induction in a patient with raised intracranial pressure can
cause cerebral ischemia. On the other hand, laryngoscopy and intubation can
raise the intracranial pressure tremendously leading to cerebral ischemia.
During the maintenance phase, hyperosmolar agents such as 20% mannitol or
3% saline are administered for brain relaxation. Steroids and anticonvulsants
are administered to reduce the cerebral edema and to prevent seizures
respectively. Avoidance of secondary insults to the brain such as hypercapnia,
hypoxemia, hypotension or hypertension, hypo- or hyperosmolality, hypo- or
hyper glycemia and hyperthermia play a significant role in postoperative
outcome.
Pathophysiology of seizures
Seizures are due to atypical firing of neurons at abnormally high
frequencies, this result in abnormal movements or experiences in an individual.
Epilepsy is a tendency to have repeated seizures. Epileptogenesis is the
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pathological process that leads to epilepsy. Irritation of the cortical brain,
genetic or metabolic abnormalities contribute to Epileptogenesis.
The risk factors for developing seizures depend on the pathology of the
tumor as well as its location.  Tumor pathology plays an important role in
Epileptogenesis. Typically a low grade glioma has higher incidence of seizures
than a high grade glioma(6). The reason for this higher incidence is not fully
understood till now. The longer survival rates in low grade gliomas as
compared with the high grade gliomas may be the reason for higher incidence
of seizures in them. Tumor cells can result in the formation of focal or remote
cell changes which are responsible for formation of a seizure focus.
Dysembryoplastic neuroepithelial tumors and gangliogliomas are low grade
tumors that are most commonly associated with seizures, probably because of
the fact that they contain neural tissue. Tumors that do not contain neural tissue
may also cause seizure by causing cellular changes such as necrosis, scar tissue
formation, edema and hemosiderin deposits. These changes are typically seen
in high grade gliomas. Epidermoid tumors though they are benign and
surgically easy to remove they are most often complicated by post craniotomy
seizures because of release of toxic contents while handling the tumor, which
can irritate the surrounding brain matter.
Tumor location also plays a critical role in the development of seizures.
Tumors in the cortical grey matter are more prone for developing seizures than
those in the infra tentorial region. The closer a tumor is to the motor cortex the
more prone it is for developing seizures. Tumor location has an influence on
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the type of seizure the patient presents with. For example, tumors in the motor
cortex present with focal motor seizures while those in the temporal lobe
present with aura of unpleasant smells and sounds. Temporal lobe tumors
present with complex partial seizures, parietal tumors present with focal
sensory seizures and occipital tumors with visual disturbances.
Figure 1: Parts of the Brain and its division into supra and infratentorium by the
Tentorium cerebelli.
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History of anticonvulsant use in Craniotomies
The beginning of antiepileptic drug use dates back to 11th May 1857,
when Charles Locock used potassium bromide to treat 52 cases of hysterical
epilepsy. The pharmacological age of anticonvulsants began with the
serendipitous discovery of Phenobarbitol by Alfred Hauptmann. He was a
psychiatry resident who lived above a ward of patients with epilepsy.
Phenobarbitol (luminal) had just begun to be used in psychiatry as a hypnotic
drug. Hauptmann sedated his patients with phenobarbitol so he could get a
good night sleep as he was continually disturbed by the epileptic patients on the
floor below. He subsequently noticed that these patient who he administered
Phenobarbitol to, slept well and also had fewer episodes of seizures.
Although Phenobarbitol was effective as an antiepileptic drug it was
highly sedative. In 1934 Tracy Putnam along with his colleague Frederick
Gibbs experimented with a number of phenyl compounds which were non
sedative. They soon discovered Phenytoin.  1936, was the year in which
Putnam administered Phenytoin for the first time to Houston Merrit who was
an epileptic. Houston Merrit soon became seizure free. More and more drugs
were discovered such as troxidone, ethosuximide and Carbamazepine in the
middle of the nineteenth century.
Pierre Eymard in 1963 discovered the antiepileptic activity of Valproic
acid while he was a resident researcher in the University of Lyon. Extensive
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clinical research was done on Valproic acid. In 1967, the sodium salt of
Valproic acid was used as an antiepileptic in France.
Benzodiazepines were recognized for the treatment of epilepsy
following their synthesis and development by Leo Sternbach, in 1960s. In 1965
Henry Gastaut published a report regarding the efficacy of diazepam in treating
status epilepticus.  His follow up paper with Clonazepam 6 years later was even
more positive. Clobazam is probably the most widely used oral benzodiazepine
for a range of refractory epilepsies. Diazepam (rectal and intravenous),
midazolam (buccal and intranasal) and Lorazepam(intravenous) are drugs of
choice for acute repetitive seizures and convulsive status epilepticus.
The modern era of anticonvulsants began in 1975 when the National
Institute of Neurological Disorders and Stroke, United States established the
Anticonvulsant Drug Development programme. Over 28,000 chemicals have
been studied and developed using target oriented design and structural
modification of existing molecules. They all have the ability to decrease
neuronal excitation or increase neuronal inhibition by one or more of
pharmacological processes, including modulation of voltage-gated cation
channels, potentiation of GABAnergic activity, inhibition of glutaminergic
processes and modification of release of neurotransmitters.
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Pharmacology of phenytoin and sodium Valproate
PHENYTOIN
DESCRIPTION:
Phenytoin sodium is a hydantoin derivative with antiepileptic properties.
Phenytoin is also a class Ib antiarrhythmic agent used to treat ventricular
arrhythmias. Phenytoin sodium is related to the barbiturates in chemical
structure, but has a five-membered ring. The chemical name is sodium 5,5-
diphenyl-2, 4-imidazolidinedione, having the following structural
formula:(Fig.2)
Figure 2: Chemical formula and Intravenous preparation of Phenytoin
MECHANISM OF ACTION:
Phenytoin exerts its antiepileptic action by acting on the motor cortex
where it promotes sodium efflux from the neurons. In this way, it tends to
stabilize neuronal membranes against hyper excitability. It reduces post tetanic
potentiation at synapses and hence prevents cortical seizure foci from
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detonating adjacent cortical areas. The brain stem areas responsible for the
tonic phase of tonic clonic seizures are maximally inhibited by phenytoin.
PHARMACOKINETICS:
It does not follow linear kinetics (non linear kinetics) as the dose is
increased elimination increases up to the point of saturation. The usual
therapeutic range is between 10-20 mg/L. Phenytoin is 90% protein bound. It
was manufactured as its sodium salt as the absorption is more reliable in this
form. Phenytoin is metabolised by cytochrome p450 mixed oxidase and only
less than 5 % is excreted unchanged. Its half life is between 10 to 40 hours.
Free phenytoin level thus depends on the level of protein therefore in hypo-
albuminemia the free concentration increases and can lead to toxicity. Table: 1
shows the conditions in which the free phenytoin levels may increase.
Table 1: Conditions that increase the levels of unbound (free) phenytoin
Insufficient albumin
(hypoalbuminemia)
Displacement by
endogenous compounds
Displacement by
exogenous compounds
Liver disease
Nephrotic syndrome
Pregnancy
Cystic fibrosis
Burns
Trauma
Malnourishment
Elderly
Hyper-albuminemia
Liver disease
Renal dysfunction
Drug interaction:
Warfarrin
Valproic acid
Aspirin
NSAIDS (with high protein
binding)
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DOSE:
Loading dose is 15mg/kg
Maintenance 5-6 mg/kg/day
USES
1. Generalised tonic clonic seizure
2. As an anti arrhythmic
3. Trigeminal neuralgia
THERAPEUTIC AND TOXIC CONCENTRATION:
The usual therapeutic range of (bound+ unbound) phenytoin is 10-20
µg/ml  in plasma for treatment of seizures. Since phenytoin is highly protein
bound (90%), it is prone for plasma protein binding displacement. In the upper
end of therapeutic range (>15µg/ml) patients experience drowsiness and
fatigue. When plasma concentration exceeds 20µg/ml, nystagmus occurs.
Above 30 µg/ml ataxia, slurred speech and in-coordination can occur. When
plasma levels reach above 40µg/ml mental status changes like decreased
mentation, severe confusion, lethargy and coma can occur. Drug induced
seizure activity has occurred at concentrations between 50-60 µg/ml(7).
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SIDE EFFECTS
Cardiovascular: severe hypotension and arrhythmias can occur when it is
infused at the rate of >50mg/min.
Neurological: At therapeutic doses phenytoin may produce nystagmus on
lateral gaze, vertical nystagmus, sedation, slurred speech cerebellar ataxia and
tremors can occur at toxic doses. Abrupt discontinuation of phenytoin can
increase seizure frequency and even progress to status epilepticus. Prolonged
use of phenytoin leads to accumulation in the cerebral and cerebellar cortex
leading to atrophy of the same.
Haematological: Megaloblastic anaemia, Agranulocytosis and Aplastic
anaemia can occur.
Pregnancy: Administration of phenytoin in pregnancy leads to fetal hydantoin
syndrome (mild mental retardation, craniofacial abnormalities, cleft lip and
palate, as it is a teratogen.
Gastrointestinal: Gingival hypertrophy
Dermatological: Side effects range from itching, rashes and hypertrichosis to
life threatening Steven Johnsons and toxic epidermolysis.
Psychiatric: Patients on phenytoin tend to have suicidal thoughts and
depression.
Metabolic: Interference with vitamin D metabolism causes severe osteoporosis
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DRUG INTERACTION:
Phenytoin is a hepatic enzyme inducer especially the CYP3A4 and
CYP2C19 families of the P450 enzyme. This enzyme is responsible for the
hepatic degradation of various drugs. Clinical relevance of this property is that
concomitant administration of steroids such as dexamethasone and
chemotherapeutic drugs can be rendered ineffective.
Antacids interfere with absorption of phenytoin; they significantly
reduce the rate and extent of absorption of phenytoin from the gut and therefore
put the user at risk of seizures.
Warfarin and Trimethoprim increase phenytoin levels by displacing
protein bound drug as well as inhibit the metabolism of phenytoin and thereby
increasing the plasma half life.
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SODIUM VALPROATE
Valproic acid is a branched chain fatty acid with antiepileptic and mood
stabilising properties. Its sodium salt (sodium valproate) is used in clinical
practice. Chemical name is sodium 2 propylpentoate (Fig.3).  It has been in use
since 45 years. It is considered a broad spectrum antiepileptic because it can be
used in generalised seizures(absence/tonic-clonic, myoclonic),partial seizures
(simple,complex, secondarily generalised) and also in refractory seizures.
Figure 3: Chemical formula and Intravenous preparation of Sodium Valproate.
MECHANISM OF ACTION:
The mechanism of action of Valproate is yet to be fully understood
however most of its antiepileptic activity is from its effect on the inhibitory
neurotransmitter GABA. Valproic acid increases the synaptosomal GABA
concentrations via activation of the major synthetic enzyme glutamic acid
decarboxylase. It also has inhibitory effect on the GABA catabolic enzymes
such as succinic semi aldehyde dehydrogenase and GABA transaminase.
34
Vaproate also reduces the excitatory neurotransmission mediated by gamma-
hydroxybutyric acid which is responsible for absence seizures. In addition to its
effect on neurotransmitters it also has a direct depressant effect on the neuronal
membrane by altering sodium and potassium conductance.
USES:
1. Epilepsy
2. Bipolar disease
3. Migraine
PHARMACOKINETICS:
Peak plasma concentrations after oral doses are achieved in 1-3 hours.
Bioavailability is 100% with oral formulations. Volume of distribution ranges
from 0.1-0.4L/kg. It is protein bound .Valproate undergoes biotransformation
via 5 metabolic pathways, majority of the drug is excreted in free form or as
glucuronide conjugates. Clearance ranges from 0.4 to 0.6l/h. It has a low
hepatic extraction ratio. Elimination half life ranges from 9-16 hours
THERAPEUTIC RANGE AND TOXICITY:
Therapeutic range is between 50-100µg/ml. At toxic level, CNS
depression occurs. It can present with depression, lethargy, encephalopathy,
myoclonus and respiratory depression.
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DOSE:
1000-2000mg/day in 2 divided doses
SIDE EFFECTS:
Increase in appetite and weight gain, liver failure, pancreatitis, hair loss,
edema, ataxia, teratogenicity, tremors, thrombocytopenia and encephalopathy.
Suicidal ideation and behaviour is also common.
In pregnant mothers use of Valproate is contraindicated as there is high
association with cleft lip and palate
DRUG INTERACTION:
Sodium Valproate is a hepatic enzyme inhibitor thereby causes many
drug interactions. When given in combination with phenytoin it increases
phenytoin free form as it displaces protein bound drug and inhibits its
metabolism.
When administered with vitamin k dependant anticoagulants, the levels
of anticoagulants may increase therefore close monitoring of INR is
recommended.
Carbapenem antibiotics, antimalarial agents such as Mefloquin and
chloroquin may decrease Valproate levels and lower seizure threshold.
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Major Anaesthetic Concerns in Supratentorial Craniotomies:
Preoperative assessment:
In addition to routine pre-anaesthetic evaluation, attention to tumor
location, size and type , presence of peritumoural edema, signs of raised ICP
are given special consideration while evaluating patients with supratentorial
tumors.
History usually reveals one sided headache, blurring of vision, nausea and
vomiting. History of loss of power in a particular limb or side gives an idea
about the location of tumor. History of seizures type, duration and anti seizure
medication that the patient is on  are noted.
Examination includes assessment of sensorium along with a thorough
assessment of central nervous system for motor and sensory deficits.
Investigations: routine preoperative blood tests such as hemoglobin, creatinine,
blood borne virus screen, electrocardiogram, chest X-ray as well as special
imaging such as CT and MRI for tumor size site, type and midline shift.
Preoperative preparation:
Patients are fasted overnight. Premedication is generally avoided if
patients have midline shift >5mm suggesting significant cerebral edema, as
over sedated patients tend to retain carbon dioxide further increasing the
intracranial pressure. Adequate blood should be cross matched and typed ready
for transfusion as required intraoperatively.
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Intraoperative management:
In addition to standard monitors recommended by ASA standards,
special monitors placed in supratentorial craniotomies include an invasive
arterial line, central venous line and neuromonitoring. Neuromonitoring
includes central sulcus mapping and  motor/sensory evoked potential
monitoring.
The major concern in neuroanaesthesia is to maintain optimal cerebral
perfusion pressure (mean arterial pressure-intracranial pressure). Cerebral
perfusion pressure is thus maintained by manipulating the ICP and mean
arterial pressure. Close hemodynamic monitoring warrants placement of an
invasive arterial line. Invasive blood pressure monitoring gives us beat-to-beat
variation in blood pressure. Risk of bleeding and venous air embolism, need to
rapidly infuse vasopressors drugs, indicate the placement of a central venous
catheter placement. The requirement for special monitoring is decided on a
case-to-case basis: neuromuscular monitoring should be used if muscle
relaxants are given during the surgery especially if used as an infusion.
Electroencephalography (EEG) based monitor such as BIS(Figure 4)or entropy
not only provide information about the depth of anaesthesia, it also helps us
titrate anaesthetics in patients with increased intra cranial pressure. It gives us
information about the occurrence of intraoperative seizures and to induce
electrical silence in presence of cerebral ischemia. Monitoring of evoked
potentials is helpful in observing intactness of specific central nervous system
pathways during surgical manipulation.
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Anaesthetic Management:
Carefully titrated induction and measures to attenuate larygoscopic
pressor response is of utmost importance in order to prevent further increase in
intracranial pressure and decrease in cerebral perfusion.
Anaesthetic aims during maintenance of anesthesia during supratentorial
surgery are:
1. Control of intracranial pressure via control of cerebral blood flow and cerebral
metabolic rate (chemical brain retractor concept).
Components of this concept encompass the following:
- Maintaining the blood Osmolality to mild hyperosmolar by giving 20%
mannitol or 3% Saline and by giving NaCl based solution.
- Intravenous anaesthetic agent (Propofol) to reduce the cerebral blood volume
by vasoconstriction.
- Mild hyperventilation – to reduce the cerebral blood flow by causing
vasoconstriction.
- Mild controlled hypertension: Maintaining the mean arterial blood pressure of
100 mm Hg to maintain the cerebral perfusion pressure.
- By maintaining normovolemia
- By maintaining normoxemia
- By positioning the patient slightly in Head-up with no jugular compression
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- By avoiding positive end-expiratory pressure
- By keeping the patient in deeper plane and avoid coughing and bucking on the
ventilator by using adequate muscle relaxant
- By avoiding excessive brain retraction
- By draining the CSF through Lumbar drainage
2. Neuroprotection through maintenance of optimal intracranial environment:
maintain a good match between cerebral substrate demand and supply.
Although some anaesthesiologists use moderate hypothermia (35͘͘͘ degrees
Celsius) to provide Neuroprotection, clinical studies have not demonstrated any
beneficial effect of the same in neurosurgical patients.
Awakening from neurosurgery mandates maintenance of stable arterial
blood pressure (and thus, cerebral blood flow and intracranial pressure), stable
oxygenation, carbon dioxide tension and normothermia. Careful attention is
paid so as to avoid coughing and bucking during extubation. Extubation is
associated with significant hemodynamic fluctuations. These fluctuations may
not be critical in usual subjects, however in neurosurgical patients careful and
smooth extubation goes a long way in postoperative outcomes. Coughing,
bucking and hypertension lead to rupture of incompletely cauterized blood
vessels and thus cause postoperative hematomas and seizures.
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Figure 4: BIS electrode placement to monitor depth of anaesthesia
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Recovery from anesthesia after supratentorial craniotomy
A conscious individual is awake and aware of surroundings and identity. Most
often consciousness is assessed by the Glasgow coma score. Initially the
Glasgow coma score was used in patients with head injury but it is now
commonly used to assess consciousness no matter what the etiology. It includes
verbal response, motor response and visual response. The minimum score is 3
and maximum is 15.  A score <8 is considered coma. Anesthesia is a way to
make a patient unconscious for the duration of the surgery so that he is unaware
of his surrounding and unable to  react to painful stimuli. This state of
unconsciousness is reversible. The duration of time necessary to awaken after
anesthesia to a state of normalcy is termed recovery time. There are many
factors which affect this time duration, they may be patient related, anesthetic
factors and drugs, duration of surgery and other organic conditions.
1. Surgical factors include:
Duration of surgery, use of excessive brain retraction, type and location
of brain tumour, presence of residual tumour, tumor bed haematoma.
2. Patient factors:
extremes of age, genetic variations, renal/hepatic disease
3. Drug related:
residual effects of opioids, benzodiazepines, long acting muscle
relaxants.
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4. Anaesthesia related:
residual anesthetic effect, opioid overdose, residual relaxant effect ,
Hypoxia, hypercarbia, acidosis, hypothermia
5. Metabolic causes:
Hyponatremia, Hypernatremia, Hypoglycemia, Hyperglycemia
Hypothermia, Hypothyroidism, Central anti cholinergic syndrome.
6. Central nervous system causes:
Central hypoxia, Cerebral edema, Seizures, Ischemia, Hemorrhage,
Local anesthetic toxicity
7. Respiratory causes:
Sepsis/ARDS, Respiratory failure, Depression Central respiratory drive
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Figure 5: A Flowchart showing the management of Delayed awakening after
anesthesia
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Seizure prophylaxis –the current stand
Seizures are one of the more serious complications of brain tumour
surgery as they can delay recovery and even cause death. Seizures occur in 20-
40% of patients with brain tumours(8). Frontal and parietal tumours and those
that are slow growing are more likely to cause seizures.
Several studies have been done to look at the incidence of seizures with
and without prophylaxis with conflicting results. Some studies have shown a
decrease in plasma levels of anticonvulsant at the end of craniotomies,
suggesting that a bolus administration of drug intraoperatively can overcome
this drop in levels. The drop in anticonvulsant levels being attributed to blood
loss and blood transfusion  during surgery, haemodilution with administration
of IV fluids, long duration of surgery and probably drug interaction with
dexamethasone(9).
Plasma phenytoin levels and incidence of seizures following craniotomy
for supratentorial brain tumors by Phunsawat et al studied 20 patients, plasma
phenytoin levels dropped by 29.6% in 14 patients and  increased by 52% in 6
patients. 3 out of 20 patients had post craniotomy seizures even with
therapeutic phenytoin levels. The cause for seizures being postoperative bleed
and cerebral edema(10).
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Additional phenytoin is frequently needed in patients undergoing
craniotomy for supratentorial tumour Umamaheshwara Rao et al -25 patients
were studied 44% had sub therapeutic phenytoin level, 2 patients had post
craniotomy seizures even with therapeutic plasma levels(11).
Changes in plasma phenytoin level following craniotomy J S Yeh et al
studied 28 patients. In this study less than 50% has preoperative therapeutic
levels, in most (89%) patients there was a decrease in phenytoin levels by 26%.
None of the patients had seizures post operatively(9).
The latest guideline on seizure prophylaxis published by the American
academy of neurology,2002 recommends the avoidance of the use of
anticonvulsants prophylactically in patients with brain tumours as they are not
beneficial in  preventing the first episode of seizure(2).
Anticonvulsant prophylaxis for brain tumor surgery : determining the
current best evidence Eli et al looked into 2 meta analyses  and recommended
that their use does not improve seizure control in these patients and hence
should be avoided.(12)
Despite these guidelines that discourage the use of anticonvulsant they
continue to be administered to patients with brain tumors by neurosurgical
practitioners, so also in our institution. The aim is to attain therapeutic levels
and steady state plasma concentration preoperatively (phenytoin- 10-20mcg/ml
and Valproate- 40-100mg/ml).
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Effect of anticonvulsants on hemodynamics depth and recovery
The older generations of anticonvulsants were known for their sedative
effects, however the currently used anticonvulsants such as Valproate and
phenytoin also have some sedative effect. A study done in Turkey by Isil
gogcegoz et al showed the reduced requirement of Propofol in patients
receiving Valproate who were undergoing ECT .The dose required to reach
BIS of 60 was lesser in those patients on Sodium Valproate(13).
Few case reports of hemodynamic disturbances with the administration
of bolus doses of phenytoin more so than Valproate.  Cardiac arrest after rapid
intravenous administration of phenytoin have also been reported(14).
Phenytoin and Valproate have been implicated in cognitive dysfunction.
Antiepileptics are administered to patients with brain tumors and cognitive
dysfunction commonly attributed to the tumor and cerebral edema, however
studies have shown that phenytoin and Valproate may be responsible for
cognitive dysfunction(3). This study aims at recognizing the possibility that
administration of large doses of antiepileptics themselves may be responsible
for early postoperative cognitive dysfunction and delay in recovery time.
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MATERIALS AND METHODS
Patient Selection and Methodology
Settings
This study was carried out in the three Neurosurgery operating theatres
and Neurosurgery Intensive Care Unit of Christian Medical College and
Hospital, Vellore.
Inclusion Criteria
1. Supratentorial brain tumours
2. Age 18-60 yrs
3. ASA grade 1,2 &3
4. Patients on single AED for more than 1 week.
Exclusion Criteria
1.Pregnancy
2.Severe LV dysfunction
3.Kidney disease
4.Liver disease
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5.H/o seizures on AED within a week
6.Surgery lasting for > 5 hours.
7.Blood loss > 30% of blood volume will be excluded.
8.Deep seated tumour which needs brain retraction
9. Preoperative GCS<15
Sample Size
Sample size: Assuming that the mean recovery time for group 1 will be
15 mins (SD=5) and for group 2 will be 25 mins (SD=6), the minimum
required number to test the significant difference between the two groups is 9
samples each. So the sample size  for this study is decided  to be 40
Since there are 4 strata ( phenytoin regular dose/Valproate regular dose/
phenytoin additional dose/Valproate additional dose) each group  will have 10
sample and hence a total sample size of 40
The calculation is done by using nmaster 2.0 software.
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Two Means - Hypothesis testing for two means
Standard deviation in group  I 5
Standard deviation in group  II 6
Mean difference 10
Effect size 1.818182
Alpha error (%) 1
Power (1- beta) % 90
1 or 2 sided 2
Required sample size per group 9
Methodology
Patients who meet the inclusion criteria for the study will receive
standardized anaesthesia as follows:
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1.Premedication:
No sedative premedication was given to all patients undergoing
supratentorial craniotomy. Routine dose of anticonvulsant dexamethasone and
ranitidine was continued as per schedule.
2. Intraoperative period
After wheeling the patient in operating room, standard monitors like
ECG, SpO2, NIBP, were connected. 18 or16 G peripheral line, 20 G arterial
line was started. First blood sample was taken for checking the anticonvulsant
level. After adequate preoxygenation with 6 L/min of 100% oxygen, patients
were induced with 1-2 µg/kg of fentanyl, 1.5 -2 mg/kg of propofol and
paralysed with 0.1 mg/kg of vecuronium.
After 3 min of ventilation and after achieving 1 MAC concentration of
isoflurane, patient’s trachea was intubated. After securing airway, anaesthesia
was maintained using 0.8-1 MAC Isoflurane in air and oxygen (40%) mixture.
FGF were reduced to 2L/ min for 20 min. Then the FGF were reduced to 750
ml- 1L/min. Temperature probe, BIS monitor and neuromuscular monitor were
connected after intubation. Muscle relaxation was maintained with infusion of
Vecuronium at 1 ug/kg/min, and its response was monitored using Train Of
Four (TOF) Ratio in neuromuscular monitoring device.
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Additional dose of 0.5 µg/kg of fentanyl and 0.5mg/kg of propofol were
given intravenously along with local anaesthetic infiltration at pin site at the
time of insertion Mayfield head clamp. 20-30 ml of 0.25% Bupivacaine with
adrenaline (5 µg/ml) was given for scalp flap infiltration.
Anaesthesia and muscle relaxation were monitored and maintained
constant as described earlier. Any additional significant sympathetic response
producing rise in heart rate and BP > 20% from the baseline was treated with
0.5 mg/kg of propofol and if required 0.5 µg/kg of fentanyl.
For patients who were supposed to receive an additional dose of
anticonvulsant, it was given during the start of bone flap removal. The drug
was administered over a period of 15-20 mins during which the changes in
haemodynamics and BIS were noted down. Intraoperatively, fluids
(crystalloid,colloid,blood) were be given according to the PPV(pulse pressure
variation) changes. PPV was maintained below 13.
While achieving haemostasis, BP was brought to pre-induction level
with small doses of vasopressors (ephedrine or phenylephrine) and IVF. During
the dural closure 0.5µg/kg of fentanyl was given along with 15 mg/kg of
paracetamol. Another 0.5 µg/kg of fentanyl , given if needed during the scalp
flap closure. 0.1 mg/kg of ondansetron was given 20 min prior to end of
surgery. Concentration of isoflurane was reduced at the time of skin closure to
keep MAC of 0.6-0.7. Isoflurane was cut off while applying skin dressing but
FGF were not increased. Xylocard 1-1.5 mg /kg was given while applying the
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skin dressing to prevent coughing while removing the May field head clamp.
FGF were then increased to 6-8L/min only after the removal of pin.
3. Reversal and recovery:
Patients were reversed using neostigmine (50 µg/kg) and glycopyrroate
(10 ug/kg). The patient was not stimulated (call their names, or suction) and the
respiratory rate was not changed to bring the CO2 up till the MAC came down
to 0.3. Time taken from stopping the isoflurane to extubation was recorded as
Extubation time. Time taken to open their eyes was noted.
4.Postoperative care and follow up:
After extubation, Second blood sample was taken for checking the
plasma level. Recovery was assessed based on time taken to open eyes, time
taken to obey commands and time to orientation to place and person
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RESULTS
In this study a total of 36 patients were studied, 19 patients received
phenytoin and 17 patients received sodium valproate. Out of 19 patients who
received Phenytoin, 12 patients received the regular dose (no bolus) and 7
patients received additional or bolus dose of phenytoin during craniotomy. Out
of 17 patients who received sodium valproate, 10 patients received additional
valproate and 7 patients received only the regular dose during surgery. Patients
who received the regular dose are marked as regular group and patients who
received additional dose are marked as additional group as shown in Table 2.
Table 2: No of patients who received the regular dose Vs additional dose:
Group
(Total No of patients)
Regular Group Additional Group
Phenytoin (19) 12 7
Sodium valproate (17) 7 10
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Demography:
Age and Body weight:
Patients between 18 and 70 years of age were recruited in this study.
The mean age of patients who received regular phenytoin was 45years and for
additional phenytoin was 43 years. The mean age of patients who received
regular sodium valproate was 45 years and for the additional dose was 44 years
. Since the age of a patient has significant impact on requirement of anaesthesia
as well as the recovery, we wanted to see whether the age distribution is
uniform even if we divide the age group further into less than 45 and more than
45 yrs. We did not see any significant difference in age distribution between
the groups.
Table 3: Age distribution between the two groups.
Groups Regular Group Additional Group
< 45 yrs > 45 years < 45 yrs > 45 yrs
Phenytoin (No of pts) 7 5 4 3
Sodium valproate (No of pts) 3 4 5 5
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There was no significant difference in distribution of age between the groups as
shown in Table 3.
The mean body weight was 59.3 kilogram for regular group and 62kilogram for
additional group. There was no difference in body weight between the two
groups.
Gender:
Out of 36 patients, there were 12 males and 7 females who received
regular dose. There were 7 males and 10 females who received the additional
dose (Figure 6a ). Over all, there were more males in patients who received
phenytoin and more females in patients who received sodium valproate
(Figure 6b).
Figure 6a: Sex distribution among two groups.
Male
63%
Female
37%
Regular group
Male
41%Female
59%
Additional group
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Figure 6b: Sex distribution among patients who received phenytoin and sodium
valproate.
In this study, our primary outcome was to assess the recovery time in
patients receiving additional Vs regular dose. The tumour type, location,
presence of preoperative seizures all can affect the recovery from anaesthesia.
So we wanted to compare the distribution of these factors between the two
groups.
Tumour Pathology:
There was no significant difference in distribution of tumour pathology
between the two groups. (Figure 7a:7b). Most patients in both groups had
meningioma; it is one of the most common benign intracranial lesions.
Following meningioma, glioma was the second common tumour type seen in
both the groups.
Female
26%
Phenytoin
Male
74%
Female
71%
Sodium Valproate
Male
29%
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Figure 7a: Distribution of tumour pathology in the Regular group
Figure 7b: Distribution of tumour pathology in the Additional group.
Meningioma
53%
Glioma
16%
Hemangioma
5%
Epidermoid
5%
Astrocytoma
10%
Other
11%
Regular group
Meningioma
44%
Glioma
11%
Cyst
5%
Epidermoid
6%
Astrocytoma
6%
Other
28%
Additional group
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Tumour location:
Tumour location also has a significant impact on recovery from
anaesthesia. Tumours located on certain areas of brain eg. the frontal cortex,
can cause delayed awakening. Most patients in both the groups had frontal
tumours, followed by parietal tumours. There was no significant difference in
tumour location between the two groups. Figure 8a: 8b showing the distribution
of tumour location between the two groups.
Figure 8a: Tumour location in Regular Group.
Frontal
47%
Parietal
37%
Occipital
5%
Temporal
11%
Regular group
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Figure 8b: Tumour location in Additional Group.
Presence of Preoperative seizures:
Presence of preoperative seizures is one of the risk factor for
development of intra and post operative seizures which can delay the
awakening from anaesthesia.
Table 4: No of patients who presented with preoperative seizures in both
groups:
Group
Regular Group (19) Additional Group (17)
Seizures
Yes
Seizures
No
Seizures
Yes
Seizures
No
Phenytoin 8 (67%) 4 (33%) 3 (43%) 4 (57%)
Sodium Valproate 2 (29%) 5 (71%) 4 (40%) 6 (60%)
Frontal
65%
Parietal
17%
Temporal
12%
Intraventricular
6%
Additional group
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In the regular group, 10/19 patients had presented with seizures. In the
additional group, 7/17 patients had presented with seizure for which they were
on anticonvulsants. There is no significant difference found between the two
groups.
No of patients with medical co-morbidities between the two groups:
Presence of medical co-morbidities can also affect the recovery of
anaesthesia. Most patients in both the Groups were ASA 1. In regular group,
8/19 patients were ASA 2 and in the Additional Group 7/17 patients were ASA
2. There  was no significant difference found between the two groups as shown
in Table 5.
Table 5: Distribution of comorbidities between the two groups
Co-morbidities Regular Group (19) Additional Group (17)
No co-morbidities 11 10
Diabetes Mellitus 2 1
Hypertension 6 5
Ischemic Heart Disease 0 1
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Duration of Anaesthesia:
The mean duration of anaesthesia was 285 min in Regular group and it
was 279 min for the additional group. There was no significant difference in
duration of anesthesia between the two groups.
Effect of administration of anticonvulsants on heart rate:
Since the Phenytoin and sodium valproate have variable effect on the
heart rate, we wanted to study the effects of anticonvulsant on heart rate
separately for phenytoin and sodium valproate. Heart rate was noted at 5 min
prior to anti convulsant administration and noted as baseline. From the time of
drug administration to next 60 mins the heart rate changes were noted at every
5 mins. A total of 13 time periods in which, the heart rate changes were
studied.
In the additional Phenytoin group, there was a drop in heart rate noted from 20
min of drug administration and it continued till the end of monitoring period,
when compared to regular group. Though the drop was clinically significant, it
was not statistically significant(p value 0.302) because of small sample size.
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Figure 9a: Dot plot comparing the effect of Phenytoin on Heart rate at various
time points between the two groups.
X- axis : Various time points of HR measurement (1=baseline 2=5min,3=10min,4=15min...13=1hour)
Y- axis:  Heart rate in beats /min , (HR- Heart Rate).
On the other hand, in the Valproate group, the heart rate was noted to be
in higher range in additional group compared to regular group, however the
difference is not statistically significant  (p value 0.602)
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Figure 9b : Dot plot comparing the effect of Valproate on Heart rate at various
time points between the two groups.
X- axis: Various time points of HR measurement (Time 1=baseline, 2=at 5min, 3=10min….13=1hour)
Y- axis: Heart rate in beats/min (HR- heart rate)
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Effect of anticonvulsants on systolic blood pressure (SBP):
Since the Phenytoin and sodium valproate have variable effect on blood
pressure, changes in blood pressure was plotted separately for phenytoin and
sodium valproate. Similar to heart rate recordings, the SBP changes were
studied at 13 time periods for both the drugs and compared.
In the Phenytoin group, the trends of systolic blood pressure were lower
in additional group compared to regular group as shown in the figure (10a ).
Though it looked clinically significant, it was not statistically significant.
(p value 0.559)
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Figure 10a : Dot plot comparing the effect of phenytoin on systolic blood
pressure between the two groups.
X- axis: Various time of SBP measurement (1=baseline,2=at 5min.3=10min….13=1hour)
Y-axis:  Systolic blood pressure in mm Hg (SBP-Systolic blood pressure)
Even in the Valproate group, the trends in systolic blood pressure were lower in
the additional group compared to regular group however this was not
statistically significant.(p value 0.521).
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Figure 10b : Dot plot comparing the effect of valproate  on systolic blood
pressure between the two groups.
X -axis : Various time points of SBP measurement (1=baseline,2=at 5min,3=10min….13=1hour)
Y-axis: Systolic blood pressure in mm Hg (SBP- Systolic blood pressure)
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Effect of anticonvulsants on diastolic blood pressure (DBP).
The diastolic blood pressure was lower in patients who received additional
phenytoin compared to regular group as shown in Figure 11a . (p value
0.556).
Figure 11a : Dot plot comparing the effect of phenytoin on diastolic blood
pressure between the two groups.
X - axis: Various time period of DBP measurement (1=baseline, 2=at 5min.3=10min….13=1hour,
Y- axis: Diastolic blood pressure in mm Hg (DBP)
In patients who received Valproate, the DBP was almost similar in both
groups at most part of the study time as shown in Figure11b . (p value 0.653)
68
Figure 11b : Dot plot comparing the effect of phenytoin on diastolic blood
pressure between the two groups.
X- axis: The various time period of DBP measurement(1=baseline,2=at 5min.3=10min….13=1hour)
Y- axis: Diastolic blood pressure in mm Hg
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Effect of anticonvulsants on Mean blood pressure (MBP):
In the phenytoin group, the mean blood pressures were lower in the
additional group when compared to the regular group which was statistically
not significant (p value 0.88)
Figure 12a : Dot plot comparing the effect of phenytoin on mean blood
pressure between the two groups.
X - axis: Various time period of MBP measurement (1=baseline, 2=at 5min.3=10min….13=1hour,
Y- axis: Mean blood pressure in mm Hg (MBP)
In the Valproate group the mean blood pressure was also lower in the
additional group when compared to the regular group across most time points.
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Figure 12b : Dot plot comparing the effect of valproate on mean blood
pressure between the two groups.
X - axis: Various time period of MBP measurement (1=baseline, 2=at 5min.3=10min….13=1hour,
Y- axis: Mean blood pressure in mm Hg (MBP)
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Effect of anticonvulsants on Bispectral index (BIS).
Since anticonvulsants can affect the depth of anaesthesia, the change in
bispectral index (BIS) was noted across 1 hour during and after administration
of anticonvulsant. It was measured using the bispectral index monitor.
Both, phenytoin and sodium valproate caused marginal drop in BIS
during and within one hour of administration of an anticonvulsant. (Figure 13a
,13b ).But there is no significant difference in BIS between patients who
received additional Vs regular dose both clinically and statistically.
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Figure 13a : Dot plot showing the Changes in BIS during and soon after
administration of phenytoin.
X - axis: Various time period of BIS measurement (1=baseline, 2=at 5min.3=10min….13=1hour,
Y- axis: BIS values (0-100)
In the Valproate group, the BIS values were measured in the same way. Across
most time points the additional group had lower BIS values which is not
significant.
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Figure 13b : Dot plot showing the Changes in BIS during and soon after
administration of Sodium Valproate.
X - axis: Various time period of BIS measurement (1=baseline, 2=at 5min.3=10min….13=1hour,
Y- axis: BIS values (30-50)
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Requirement of Propofol and Fentanyl:
Requirement of propofol and fentanyl was almost similar between the two
groups. Consumption of propofol was slightly higher in regular group but it is
not statistically significant.
Table 6 : Showing the requirement of fentanyl and propofol between the two
groups
Requirement of vasopressors to maintain haemodynamics:
The median value of phenylephrine  was higher is the additional group
400 (150-800) when compared with the regular group 350(0-800).The median
dose  of noradrenaline in  the additional group is 80 (0-340) while in the
regular group it was 160 (0-200) as shown in Table 7 :
Regular group
(Mean ± SD)
Additional group
(Mean ±SD)
Fentanyl (µg) 260± 62.2 251±76
Propofol (mg) 296± 73 251± 65
75
Table 7 : Showing the requirement of vasopressors between the two groups:
Vasopressors Regular group
Median (IQR 25-75)
Additional group
Median (IQR 25-75)
Phenylephrine (µg) 350 (0-800) 400 (150-800)
Noradrenaline (µg) 160 (0-200) 80 (0-340)
Figure 14a: Box plot showing the use of Noradrenaline in regular and
additional group
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Figure 14b: Box plot showing the use of phenylephrine in regular and
additional group.
Changes in anticonvulsant levels during craniotomy:
The rational for administration of bolus anticonvulsant during
craniotomy, is that there is a possibility of declining plasma levels due to
administration of intravenous fluid and blood / blood products during surgery.
Lower plasma levels can lead to post craniotomy seizures because of multiple
triggering factors during the immediate postoperative period such as cerebral
edema, presence of post operative haematoma and brain contusion due to
retraction. So we wanted to study the change in plasma level before and after
craniotomy and correlate this change with IVF administration.
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In the regular Phenytoin group the mean pre- induction plasma value was
10.03µg/ml and the post craniotomy value was 9.755µg/ml. The mean drop in
anticonvulsant level was 0.27µg/ml. In the additional Phenytoin group, the
mean pre-induction plasma level was 10.87 µg/ml and post craniotomy level of
10.824 micrograms/l showing a drop of only 0.05 micrograms/l. (Table 8 )
In the regular valproate group the mean pre-induction plasma level
was 78.47 µg/ml and post craniotomy mean levels were 70.87µg/ml, a mean
drop was by 7µg/ml. In the additional valproate group the mean pre
induction level was 60.79 µg/ml and post craniotomy was 80µg/ml, an increase
by 20 µg/ml. (Table 8)
Table 8 : Showing change in plasma anticonvulsant level pre and post
craniotomy.
Groups Regular dose Additional dose
Phenytoin (µg/ml)
Pre-Surgery
Post surgery
10.03
9.755
10.87
10.824
Sodium Valproate(µg/ml)
Pre surgery
Post surgery
78.47
70.087
60.79
80
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Figure 15: Box plot Showing change in anticonvulsant level between the two
groups for both Phenytoin and sodium valproate separately:
X axis: study groups
Yaxis: change in anticonvulsant level (postoperative plasma anticonvulsant level-preoperative
anticonvulsant level)
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In patients who received Phenytoin, despite anticonvulsant being started
more than 14 days prior to surgery to maintain steady plasma levels only 31%
had a therapeutic range, 57% had subtherapeutic level and 10% had supra
therapeutic level.
In patients who received Valproate , 52% of patients had a therapeutic range,
30% had less than therapeutic range and 17% had above therapeutic range. At
the end of craniotomy, 13% had less than therapeutic range, 70% had within
therapeutic range and 17 % had above therapeutic range.
Table  9: Comparing the number of patients who had sub, therapeutic, supra
therapeutic concentration of anticonvulsant before and after surgery.
Groups Blood concentration Pre surgery
No of patients
(Incidence)
Post surgery
No of patients
(Incidence)
Phenytoin
(µg/L)
< 10 (Sub therapeutic) 11   (58%) 10    (56%)
10-20 (Therapeutic) 6     (32%) 7    (39%)
> 20 (supra therapeutic) 2     (10%) 1    (5%)
Sodium
valproate
(µg/L)
<50 (Sub therapeutic) 5     (30%) 2   (13%)
50-100(Therapeutic) 9     (52%) 12    (70%)
>100 (Supra
therapeutic)
3     (17%) 3    (17%)
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Correlation between IV fluids administered and drop in plasma
anticonvulsant level:
In this study we found that there is a definite correlation between the
amount of IVF administered and the drop in plasma anticonvulsant level, both
in the regular as well as in the additional group.  The drop was very significant
in the regular group (p value 0.004) compared to additional group (P value
0.318). Figure 16a and 16b Scatter plot showing the correlation in regular and
additional group respectively. As the blood loss increases, there is a definite
decline in plasma level of anticonvulsant level.
Figure 16a : Scatter plot showing the correlation between the drop in plasma
anticonvulsant level and the amount of intravenous fluids administered in the
Regular group.
X axis: Intravenous fluids in milliliters
Y axis: change in anticonvulsant level (postoperative plasma anticonvulsant level-preoperative
anticonvulsant level)
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Figure 16b : Scatter plot showing the correlation between the drop in plasma
anticonvulsant level and the amount of intravenous fluids administered in the
Additional group.
*AED=Antiepileptic drug
X axis: Intravenous fluids in milliliters
Y axis: change in anticonvulsant level (postoperative plasma anticonvulsant level-preoperative
anticonvulsant
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Effect of anticonvulsants on recovery from anaesthesia.
The recovery time for 3/ 36 patients were on the extreme range. This
extreme range affected the mean value and the standard deviation. So, we have
taken the median value with the interquartile range (IQR 25-75) for each
parameter.
The time of ETT removal, time to open eyes on call, time taken to obey
commands, time to orientation are shown in table with the median value and
interquartile range (25-75). When we analyzed the results as two groups
(additional Vs regular dose) there were no difference found between the two
groups in all four parameters (Table 10).
Table 10 :Showing the recovery time between the regular Vs additional
group.
Time Regular group
Median (IQR 25-75)
Additional group
Median (IQR 25-75)
P value
Time to ETT removal(min) 15(13-20) 14(13-19) 0.75
Time to open eyes(min) 23(15-31) 24(16-27) 0.824
Time to obey commands (min) 33(25-45) 33(24-67) 0.824
Time to orientation(min) 42(35-53) 57(37-128) 0.208
83
We have done a subgroup analysis of recovery parameters in patients
receiving Phenytoin and sodium valproate separately to see whether the drug
has a significant impact on recovery. This subgroup analysis revealed patients
who received additional Phenytoin had a significant delay in eye opening on
call (22 min:26 min), time to obey commands (33min:48min) and time to get
orientation (42min:120min) when compared to patients on regular dose group.
Though this time difference is clinically significant, it was not statistically
significant.
Interestingly, in the sodium valproate group, we did not find any
significant difference both, clinically or statistically between the regular Vs
additional dose group.
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Table 11 : Showing the subgroup analysis of recovery parameters between the
Phenytoin and sodium valproate group.
Recovery parameters Phenytoin
Median (IQR 25-75)
Sodium Valproate
Median (IQR)
Regular Additional Regular Additional
Time to ETT removal (min) 16 (13-19) 14 (13-15) 14 (12-21) 17(12-21)
Time to open eye on call
(min)
22 (15-29) 26 (18-38) 30 (13-48) 21(14-26)
Time to obey commands
(min)
33 (25-44) 48 (30-120) 37 (21-53) 31 (20- 48)
Time to orientation (min) 42 (35-52) 120 (39-210) 42 (35-53) 51(31-102)
85
Incidence of post operative seizures:
Despite being on prophylactic anticonvulsant before craniotomy 5 out of
36 developed post operative seizures.1 patient in regular phenytoin group, 1
patient in the additional phenytoin group, 1 patient in the regular Valproate
group and 2 patients in the additional Valproate group.(Table 12)
Table 12: Incidence of seizures in each of the groups
Group Regular Group
No of pts (incidence %)
Additional Group
No of Pts (Incidence %)
Phenytoin 1/12 (8.3%) 1/7 (14.3%)
Sodium valproate 1/7 (14.3%) 2/10 (20%)
Out of 2 patients who had post operative seizures in regular group, one had sub
therapeutic level and one had normal therapeutic level during the post operative
period. Out of 3 patients in the additional group one had sub therapeutic, one
had normal therapeutic level and the other one had supratherapuetic level.
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DISCUSSION
This study was undertaken to assess whether an additional dose of
anticonvulsant administered during surgery has an impact on recovery from
anaesthesia, intraoperative haemodynamics, depth of anaesthesia, on plasma
anticonvulsant level and the incidence of post operative seizures.
We found more females in patients who received sodium valproate
compared to Phenytoin. This difference may be due to the fact that the
incidence of Steven Johnson syndrome is higher in female patients who are
diagnosed with meningioma who were on Phenytoin. So Phenytoin is not
generally given to female patients with suspected meningioma. The exact cause
for this skin reaction is not known. Meningioma was the commonest tumour in
both, regular as well as the additional group.
Recovery from anaesthesia:
There are various factors which can alter the recovery from anesthesia in
a neurosurgical case such as age, tumor pathology, location, brain retraction,
and presence of cerebral edema and so on. In our study, we had carefully
selected patients in both groups so that the distributions of age, tumour type,
location and tumour volume all were equal. Also, most patients had surface
tumour of less than 4 cm in size so, the chances of brain retractions and brain
edema induced delayed recovery is very minimal in both the groups.
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There are various anaesthetic factors which can cause delay in recovery.
The intraoperative factors which can cause delayed awakening such as
hypoxia, hypercarbia, hypo or hyperglycemia, hypothermia, acute
hyponatremia all were avoided and ruled out in every patient. Even long
duration surgeries (> 5 hrs) can affect the recovery, in this study if the surgical
duration is more than >5 hours we had excluded those patients. There was no
difference in duration of anesthesia between the two groups.
Our study was the first one, to study the effect of anticonvulsant on
recovery from anaesthesia. We had measured the anticonvulsant level pre and
post surgery and correlated it with the recovery time. Since it was possible
only, to measure the plasma level of Phenytoin and sodium valproate we had
taken patients who were on those anticonvulsants. In this study we have found
that the administration of bolus phenytoin increased the recovery time to obey
commands by >15 min and increased the orientation time by > 1 hour when
compared to regular dose group. Aggressive use of an anticonvulsant can also
cause delay in awakening. There were 5 patients whose recovery time (Time to
orientation) was > 2 hours, those plasma levels were within the therapeutic
range. This can be explained by the sedative and hypnotic effects of phenytoin
even in therapeutic range causing delayed recovery. There are reports of acute
administration of Phenytoin causing delayed recovery in the literature (15).
Few studies have shown that long term administration of Phenytoin causing
cognitive dysfunction(3).
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On the other hand there is no significant delay in recovery of patients who
received additional valproate when compared to regular group. This may be
due to the fact that sodium valproate has less sedative and hypnotic effect
compared to Phenytoin(3)(16).
Haemodynamics:
Phenytoin is a class I b anti-arrhythmic and it blocks the sodium
channels in the cardiac tissue and causes sinus arrest and junctional
bradycardia(14). Intravenous Phenytoin administered at the rate of > 50mg/min
is not advised for the above reason. There are case reports of oral phenytoin
causing sinus bradycardia and asystole are available in the literature (14) In this
study, we had administered the anticonvulsant during the start of first burr hole
time over a period of 20 mins. The drugs were administered during the bone
flap removal so that the change in haemodynamics is attributed only to the drug
effect because of minimal stimulation during this time period. The heart rate
change was observed while administering both regular as well as the bolus dose
of Phenytoin. The drop in heart rate was more in the additional Phenytoin
group as expected because of its anti-arrhythmic effect. In Valproate group
there appears to be an increase in heart rate over time in the additional group
when compared to the regular group. This can be explained by its minimal
effect on heart rate.
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In the additional Phenytoin group, the mean arterial pressures was lower
and amount of vasopressors used to maintain stable haemodynamics were
higher proving that Phenytoin caused more haemodynamic fluctuations. In our
study, we found that the influence of Valproate on haemodynamics was less
apparent even in additional group. This was proven by the fact that the need for
vasopressors is also less with use of sodium valproate. It has been reported that
compared to Phenytoin, sodium valproate causes less haemodynamic instability
such as hypotension and bradycardia. A study published by eHealth me on
adverse effect of sodium valproate on > 12,000 patients and found the
incidence of hypotension was only 2.8% which was updated on August 2015.
But, there are case reports of hypotension caused by sodium valproate are also
reported in the literature(17). In these reports, the patients were very old (>70
yrs) or very young (<10 yr) this could the reason for hypotension.
The sedative properties of anticonvulsants can increase the depth of
anaesthesia as measured by the bispectral index (BIS) monitor and it may be
one of the reasons for delayed recovery from anaesthesia. A study done by
Gokben Hizli et al showed that decrease in the amount of Propofol needed to
reach a BIS value of 60 in patients who were pre-treated with Valproate for
bipolar affective disorder (BPAD) during electro convulsive therapy
(ECT)(18). Study by Bithal PK has shown that preoperative administration of
Phenytoin increases the anesthetic depth which was monitored by BIS and also
reported that it reduces the haemodynamic response to laryngoscopy and
intubation(19).In our study we have noted that there is a marginal decrease in
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BIS numbers while administration of both anticonvulsants. But the drop was
not significant between the regular group and the additional group.
Incidence of post operative seizure:
The American academy of neurology guidelines (2002) suggested that
prophylactic anticonvulsants for craniotomy is not effective in preventing the
first episode of seizures post craniotomy. (2) In our study a total of 5 patients
had seizures in the immediate post operative period. These five patients were
analyzed in detail.
The first patient presented with seizures and was started on Phenytoin
100 mg three times daily 60 days before surgery and was continued
intraoperatively. The pathology was an epidermoid tumor, and her pre-
craniotomy plasma level and the post craniotomy level was 2.5 µg/ml and 4.65
µg/ml respectively. The second patient had a frontal meningioma and did not
present with seizures preoperatively, was started on Valproate 500 mg two
times daily which was continued intraoperatively, her pre, post craniotomy
plasma level of Valproate was 75 µg/ml and 44 µg/ml which is lesser than the
therapeutic range. The third patient had a frontal cavernoma and presented with
one episode of seizure. She was started on Valproate 14 days prior to surgery
and her pre craniotomy Valproate level was 66 µg/ml, was given an additional
500 mg of Valproate during craniotomy, post craniotomy plasma value was 90
µg/ml, well within therapeutic range. But she had multiple episodes of post
operative seizures and was re-explored was found to have a residual tumor. The
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fourth patient underwent a frontal craniotomy for frontal meningioma, had
seizures preoperatively was on Valproate for 11 days prior to surgery was
given 900mg valproate intraoperatively. Her pre and post craniotomy Valproate
level was 76µg/ml and 104µg/ml. Fifth patient had a temporal epidermoid who
presented with pre operative seizures was started on Phenytoin preoperatively
was given a bolus of phenytoin 300mg intraoperatively, her plasma values
were 8 and 10 µg/ml at end of surgery.
Out of 5 patients who had post operative seizures 4 of them had presented
with preoperative seizures. So it is one of the major risk factors for developing
post operative seizures. Out of 5 patients who developed post operative seizure,
2 of them had subtherapuetic plasma level. We did not find correlation
between the plasma level and occurrence of post operative seizures. Since our
sample size was too small we cannot comment on plasma level and the
occurrence of post operative seizures.
In our study we found that despite of starting the anticonvulsant more
than two weeks prior to surgery, 58% patient who were taking Phenytoin had
sub-therapuetic level. Our study results were almost correlating with study
done by Uma maheswara Rao et al in which they have showed that despite of
starting preoperative phenytoin  7 days prior to surgery, 50% of patients had
subtherapeutic levels (11). We have found that compared to Phenytoin, only
30 % patients had subtherapuetic level in those who received sodium valproate.
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We have also found that there was a strong correlation between the amount of
IVF administered and decline in plasma level. Also there was a strong
correlation between the amount of blood loss and decline in plasma level.
Limitations
1. One of the major limitations of our study was small sample size. So, our
study results have to be interpreted with caution. We are planning to continue
the study in future to increase the sample size and the power of the study. Then
our results can be interpreted better and can bring about a change in clinical
practice on day to day basis.
2. Our primary outcome was to see whether administration of additional
anticonvulsant delays the recovery from anaesthesia. Main surgical reason for
delayed recovery while operating the superficial lesions is cerebral edema. We
did not do CT brain to rule out cerebral edema or presence of residual tumour
or tumour bed haematoma for all patients who had delayed recovery.
3. For those patients who had focal seizure in the immediate post operative
period, midazolam was administered which further delayed recovery time.
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Strengths
1. This study is the first one to compare the recovery time from anaesthesia in
patients receiving a regular dose of an anticonvulsant with those patients who
received an additional dose.
2. We had selected the patients carefully to rule out surgical and non surgical
confounders to our best of our ability and carried out the study so that delay in
recovery can be attributed to anticonvulsant.
3. To our knowledge, this study is the first one to compare the correlation of
amount of IVF administered and decline in plasma level of anticonvulsant.
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CONCLUSION
Administration of additional dose of Phenytoin causes delay in recovery,
haemodynamic fluctuation during surgery. Administration of additional dose of
sodium valproate did not affect either the recovery time, or the
haemodynamics. Presence of preoperative seizures is one of the significant risk
factor for developing post operative seizure.  Since there is a correlation
between the amount of IVF administered, blood loss and the decline in plasma
level of anticonvulsant, administration of an additional anticonvulsant in
patients who are resuscitated with large amount of IVF will definitely help to
restore the plasma anticonvulsant level. Due to the small sample size, it is very
difficult to comment on occurrence of post operative seizures and the plasma
anticonvulsant level. This warrants larger randomized control trial to see the
correlation statistically. This study gave us an insight into a probable reason for
delay in recovery post craniotomy.
95
REFERENCES
1. Perks A, Cheema S, Mohanraj R. Anaesthesia and epilepsy. British Journal
Anaesthesia. 2012 April 1;108(4):562–71.
2. Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al.
Practice parameter: Anticonvulsant prophylaxis in patients with newly
diagnosed brain tumors: Report of the Quality Standards Subcommittee of the
American Academy of Neurology. Neurology. 2000 May 23;54(10):1886–93.
3. LFM Beenen, HAM van Alphen. cognitive effect of phenytoin and valproate.
Journal of neurology neurosurgery psychiatry; 1999.
4. CBTRUS - 2014 CBTRUS Fact Sheet [Internet]. [cited 2015 Sep 27].
Available from: http://www.cbtrus.org/factsheet/factsheet.html
5. Manoharan N, Julka PK RG. Descriptive epidemiology of primary brain and
CNS tumors in Delhi, 2003-2007.
6. Melanie S.M, Van Breemen CJV. Optimal seizure management in brain tumor
patients -
7. Wu MF, Lim WH. Phenytoin: A Guide to Therapeutic Drug Monitoring. Proc
Singap Heal Vol. 2013;22(3):198.
8. Koubeissi M. Do we need seizure prophylaxis for brain tumor surgery?
Epilepsy Curr. 2014;14(1):24–5.
9. Yeh JS, Dhir JS, Green AL, Bodiwala D, Brydon HL. Changes in plasma
phenytoin level following craniotomy. Br J Neurosurg. 2006 Jan;20(6):403–6.
10. Phunsawat A. Plasma Phenytoin Levels and Incidence of Seizure in Patients
Undergoing Craniotomy for Supratentorial Brain Tumors. J Anesth Clin Res
[Internet]. 2012 [cited 2015 May 20];03(11).
96
11. Radhakrishnan M, Devaraj ND, Rao UGS, Subhash MN. Additional phenytoin
is frequently needed in patients undergoing craniotomy for supratentorial
tumour: Eur J Anaesthesiol. 2008 Jul;25(7):601–3.
12. Sayegh ET, Fakurnejad S, Oh T, Bloch O, Parsa AT. Anticonvulsant
prophylaxis for brain tumor surgery: determining the current best available
evidence: A review. J Neurosurg. 2014;121(5):1139–47.
13. Isil gogcegoz  gokben hizli sayar. valproate on depth.pdf. Neuropsychiatric
disease and treatment; 2014.
14. Oral Phenytoin Toxicity Causing Sinus Arrest: A Case Report [Internet]. [cited
2015Sep3].Availabl from: http://www.hindawi.com/journals/cric/2014/851767/
15. Sangeeta Sahoo, Manpreet Kaur,Chhavi Sawhney A mishra. An unusual cause
of delayed recovery from anesthesia [Internet]. [cited 2015 Sep 27]. Available
from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409972/
16. Davis, Rick; Peters, David H.; McTavish, Donna. Valproic Acid: A
Reappraisal of its Pharmacological Properties and Clinical Efficacy in
Epilepsy. 1994
17. ota KS. Probable valproate sodium-associated hypotension. - PubMed - NCBI
[Internet]. [cited 2015 Sep 27]. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/20624617
18. Hizli Sayar G, Eryilmaz G, Semieoglu S, Ozten E, Gul IG. Influence of
valproate on the required dose of propofol for anesthesia during
electroconvulsive therapy of bipolar affective disorder patients. Neuropsychiatr
Dis Treat. 2014 Mar;433.
19. Bithal PK, Pandia MP, Chouhan RS, Prabhakar H, Rath GP, Dash HH, et al.
Effects of Phenytoin therapy on bispectral index and haemodynamic changes
following induction and tracheal intubation. Indian J Anaesth. 2009;53(2):187.
97
APPENDIX
List of Figures :
Figure 1: Parts of the Brain and its division into supra and infratentorium by the
Tentorium cerebelli.
Figure 2: Chemical formula and Intravenous preparation of Phenytoin
Figure 3: Chemical formula and Intravenous preparation of Sodium Valproate.
Figure 4: BIS electrode placement to monitor depth of anaesthesia
Figure 5:A Flowchart showing the management of Delayed awakening after
anesthesia:
Figure 6a: Sex distribution among two groups.
Figure 6b: Sex distribution among patients who received phenytoin and sodium
valproate.
Figure 7a: Distribution of tumour pathology in the Regular group
Figure 7b: Distribution of tumour pathology in the Additional group.
Figure 8a: Tumour location in Regular Group.
Figure 8b: Tumour location in Additional Group.
Figure 9a: Dot plot comparing the effect of Phenytoin on Heart rate at various
time points between the two groups.
Figure 9b : Dot plot comparing the effect of Valproate on Heart rate at various
time points between the two groups.
Figure 10a : Dot plot comparing the effect of phenytoin on systolic blood
pressure between the two groups.
Figure 10b  : Dot plot comparing the effect of valproate  on systolic blood
pressure between the two groups.
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Figure 11a  : Dot plot comparing the effect of phenytoin on diastolic blood
pressure between the two groups.
Figure 11b  : Dot plot comparing the effect of phenytoin on diastolic blood
pressure between the two groups.
Figure 12a : Dot plot comparing the effect of phenytoin on mean blood
pressure between the two groups
Figure 12b : Dot plot comparing the effect of valproate on mean blood pressure
between the two groups.
Figure 13a : Dot plot showing the Changes in BIS during and soon after
administration of phenytoin.
Figure 13b  : Dot plot showing the Changes in BIS during and soon after
administration of Sodium Valproate.
Figure 14a: Box plot showing the use of Noradrenaline in regular and
additional group
Figure 14b: Box plot showing the use of phenylephrine in regular and
additional group.
Figure 15: Box plot Showing change in anticonvulsant level between the two
groups for both Phenytoin and sodium valproate separately:
Figure  16a  : Scatter plot showing the correlation between the drop in plasma
anticonvulsant level and the amount of intravenous fluids administered in the
Regular group.
Figure 16b  : Scatter plot showing the correlation between the drop in plasma
anticonvulsant level and the amount of intravenous fluids administered in the
Additional group.
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PATIENT INFORMATION SHEET
NAME OF STUDY: ANTIEPILEPTIC DRUG LEVELS AND ITS EFFECT ON
WAKING UP FROM ANAESTHESIA IN PATIENTS UNDERGOING BRAIN
TUMOUR SURGERY
WHAT IS EPILEPSY?
Brain tumours and surgery for brain tumours can cause seizures . Seizure or epilepsy
is a disorder of abnormal electrical activity in the brain leading to abnormal and
involuntary  movement in a part or whole body. Seizures can cause a state of
unconsciousness, biting of the tongue and bleeding, aspiration, decreased oxygen in
the brain and brain swelling.
WHAT ARE ANTIEPILEPTIC DRUGS?
Antiepileptic drugs are drugs given to prevent seizures/fits. Commonly used drugs are
Phenytoin, sodium valproate. These drugs are usually given to patients undergoing a
surgery for brain tumour removal in certain areas of brain.
WHY SHOULD IT BE GIVEN BEFORE SURGERY FOR BRAIN TUMOURS?
Surgery for brain tumour removal involves opening the skull bone and removing the
tumour from the brain. This surgery itself or even the brain tumour can cause seizures
therefore these drugs are given to prevent seizures especially during and after the
surgery
WHAT IS GENERAL ANAESTHESIA?
General anaesthesia is a type of anaesthesia in which you will be given medicines to
remain unconscious throughout the period of surgery to be unaware of surgery and
pain produced during surgery. Once you are made unconscious, you will not
remember any event occurring in that surgical time. During this period your blood
pressure, heart rate, blood oxygen levels etc will be continuously monitored and get
treated by the attending anaesthesiologist if needed. At the end of surgery, you will be
again woken up and will be shifted to ICU once you completely recover from
anaesthetic effects.
WHAT WILL BE DONE AS A PART OF THIS STUDY UNDER
ANAESTHESIA?
In our study, we want to see and compare whether administration of extra dose of
same antiepileptic drugs what you are receiving has an added effect on anaesthetic
medicine. We also want to measure the blood level of antiepileptic drug after giving
the additional dose  to see if it has an impact on waking up from surgery. You will be
given General anaesthesia for the surgery.  You will receive all the medication as per
our standard of practice. Additionally, we will put one electrode on your forehead to
monitor the depth of your sleep during the entire surgery.
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In our study we are dividing the patients in to two groups, Group 1 and Group 2.
Group 1 patients will receive extra dose as per surgeon’s preference and group 2
patients do not receive any additional dose but you will receive the regular dose.
During anaesthesia all vitals will be monitored and documented as a routine protocol.
Depth of your sleep also will be monitored during surgery. Two blood samples will be
taken, one in the beginning and one at the end of surgery to check the blood levels of
antiepileptic drugs.  At the end of anaesthesia, time taken for you to wake up will also
be noted down and will be compared with blood levels of your antiepileptic
medication. Post operative seizure occurrence will also be documented.
WILL THERE BE ANY ADDITIONAL COST INVOLVED?
Cost of blood tests will be borne by the study. Confidentiality will be maintained at all
times.
WHAT ARE THE RISKS AND BENEFITS TO ME IF I TAKE PART?
There are no risks to being a part of the study. There are no additional invasive
procedures/discomfort involved in this study .By being a part of this study benefits is
anticonvulsant levels will be monitored and the adequacy of current dosing regimens
during surgery can be assessed.
NUMBER OF PARTICIPANTS INCLUDED IN THIS STUDY AND
RESPONSIBILITIES
As a part of this study a total number of 40 patients will be included. After
anaesthesia has been administered  one  blood sample will be taken  and a second
sample after surgery. Recovery from anaesthesia  will be assessed every 15 minutes
until the participant is fully oriented and obeying commands. The participant will be
monitored for the next 48hours for any episode of seizures.
participation is voluntary and the participant may withdraw from the study at any
point , refusal will not involve any penalty or loss of benefits to which the participant
is otherwise entitled.
Contact:
Rosen Roy Mathew
Dept. of anaesthesia
christian medical college
vellore
phone number :9626150062
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DATA SHEET:
TITLE OF STUDY: An observational study comparing the recovery time in patients
receiving additional anticonvulsant dose intraoperatively Vs those receiving regular
dose during supratentorial craniotomy.
DEMOGRAPHY
NAME
HOSPITAL
NUMBER
AGE
SEX
DIAGNOSIS
PREOPERATIVE DETAILS
SEIZURE HISTORY: GTCS/ PARTIAL
ANTICONVULSANT  CURRENTLY IN USE: PHENYTOIN/ VALPROATE
DOSING SCHEDULE
TIME
DOSE
DURATION SINCE START OF ANTIEPILEPTIC THERAPY:
COMORBIDITIES: Diabetes/ Hypertension/ Asthma/ Ischemic heart disease
INTRAOPERATIVE DATA
ANTICONVULSANT ADMINISTERED INTRAOPERATIVELY:
TIME OF ADMINISTRATION:
DOSE ADMINISTERED:
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HEMODYNAMIC CHANGES DURING ANTICONVULSANT
ADMINISTRATION
NEED FOR VASOPRESSORS PNP/NORAD- DOSE
TOTAL DOSE OF FENTANYL GIVEN (including the induction dose) :
TOTAL DOSE OF PROPOFOL GIVEN (including the induction dose):
DURATION OF SURGERY: DURATION OF
ANAESTHESIA:
BLOOD LOSS DURING SURGERY:
IV FLUIDS ADMINISTERED
EXTUBATION
TIME 0(BEFORE
AED )
5MIN 10MIN 15MIN 20MIN 30MIN 35MIN 40MIN 45MIN 50MIN 55MIN 1HOUR
HEART
RATE
SYSTOLIC
DIASTOLIC
MEAN
BIS
MAC
CRYSTALLOID
COLLOID
BLOOD
BLOOD PRODUCTS
Time of stopping isoflurane
DURATION
Time of removal of ETT
(Extubation time)
Time of Eye opening on call
Time of obeying command
(squeezing examiners hand, bending
legs)
Time to get oriented to person and
place (what is your name ? and
Which hospital are you in?
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POST OPERATIVE DATA:
Pre op plasma anticonvulsant level:
Post op plasma anticonvulsant level:
Episodes of seizure in 48hrs: Yes/ No Number of episodes :
Time taken for obeying commands and orientation to person and place in ICU.
Parameter At
arrival
At
15
min
At
30
min
At
45
min
At
1hr
1:15 1:30 1:45 2hr 2:30min 3hour 3:30min 4 hours
Time taken to
obey command
(squeezing
hand, bending
legs)
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Time to get
oriented to
person and
place
(What is your
name?, What is
the name of the
hospital)
Yesno Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
no
Yes
no
Yes
no
Yes
No
Yes
No
105
Informed Consent form to participate in a research study
1. Study Title: AN OBESERVATIONAL STUDY COMPARING THE RECOVERY
TIME IN PATIENTS RECEIVING ADDITIONAL ANTICONVULSANT DOSE
INTROPERATIVELY VS THOSE RECEIVING REGULAR DOSE DURING
SUPRATENTORIAL CRANIOTOMY.
Study Number: ____________
Subject’s Initials: __________________ Subject’s Name:
_________________________________________
Date of Birth / Age: ___________________________(Subject)(i) I confirm that I have read and understood the information sheet dated____________ for the above study and have had the opportunity to askquestions. [  ](ii) I understand that my participation in the study is voluntary and that I amfree to withdraw at any time, without giving any reason, without mymedical care or legal rights being affected. [  ](iii) I understand that the investigators of the clinical trial, others working onthe Investigators behalf, the Ethics Committee and the regulatoryauthorities will not need my permission to look at my health records bothin respect of the current study and any further research that may beconducted in relation to it, even if I withdraw from the trial. I agree to thisaccess. However, I understand that my identity will not be revealed in anyinformation released to third parties or published. [  ](iv) I agree not to restrict the use of any data or results that arise from thisstudy provided such a use is only for scientific purpose(s). [  ](v) I agree to take part in the above study. [  ]Signature (or Thumb impression) of the Subject/Legally AcceptableDate: _____/_____/______
Signatory’s Name: _________________________________ Signature:Or
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Representative: _________________Date: _____/_____/______Signatory’s Name: _________________________________
Signature of the Investigator: ________________________Date: _____/_____/______Study Investigator’s Name: _________________________
Signature or thumb impression of the Witness: ___________________________Date: _____/_____/_______Name & Address of the Witness: ______________________________
